| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | atebimetinib first-line pancreatic cancer | Phase 3 | — | Small Molecules | Oncology | ||
Phase 3 data readout example | atebimetinib first-line pancreatic cancer | Phase 3 | — | Small Molecules | Oncology | ||
Phase 3 data readout example | atebimetinib first-line pancreatic cancer | Phase 3 | — | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Immuneering Corporation$4.54
+0.1 (+2.25%)
C 47Pipeline Score Undervalued Pharma · Clinical
Market Cap
348.72 M
EPS
-1.17
P/E Ratio
-
Value Trade
8.67 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
10.65 M
Operating CF
-18.43 M
Total Assets
214.81 M
Total Liabilities
8.29 M
Equity
206.52 M
D/E Ratio
12,345
5.69 %
Week
-3.58 %
1 Month
2.67 %
3 Month
-22.45 %
6 Month
-72.36 %
5 Year
-72.36 %
All Time
Cash Data
Cash Position
198.64 M
Monthly Burn
6.14 M
Runway
31.2 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
936.20 K
52 Week Range
1.56 - 10.08
% held by Insiders
13.67 %
% held by Institutions
47.19 %
Enterprise Value
195.75 M
Total Shares
64.66 M
Short %
22.75 %
Float Shares
55.93 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C47
Pipeline Score $1.3B
Pipeline ValueUndervalued
Valuation Signal3
Drugs Scored3.8x
rNPV / MCap Top 72%
Micro Cap (rank 254 of 905)
Percentile RankImmuneering Corporation carries a moderate pipeline score (47/100), with $3.3B risk-adjusted pipeline value, led by IMM-1-104 Monotherapy in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMM-6-415 Small molecule | Advanced Solid Tumor (Phase 1) | Phase 1 | NCT06208124 | 5% | $1.6B | COMPLETED | 30 | - | - | Apr 30, 2025 | - | May 28, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
atebimetinib (IMM-1-104) | pancreatic cancer | Phase 2a | 2025-07-10 | |||
atebimetinib (IMM-1-104) | pancreatic cancer | Phase 2a | 2025-07-10 | |||
atebimetinib (IMM-1-104) | pancreatic cancer | Phase 2a | 2025-07-10 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IMRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMRX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
IMRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMRXImmuneering Appoints Andrew Gengos as Chief Financial Officer
Immuneering Corporation has appointed Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Gengos, previously CFO at Terns Pharmaceuticals, will oversee financial strategy and corporate development as the company progresses its lead oncology candidate, atebimetinib, currently in Phase 3 trials for pancreatic cancer. His extensive experience in biotech is expected to enhance Immuneering's growth.
Read more →IMRXImmuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Immuneering Corporation has announced that the first patient has been dosed in the MAPKeeper 301 pivotal Phase 3 trial, which studies the combination of atebimetinib and modified gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The trial aims to demonstrate the efficacy and safety of this new treatment regimen compared to standard therapy. Overall survival is the primary endpoint, with additional metrics being evaluated, and topline data is expected to be available in mid-2028.
Read more →IMRXImmuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Corporation presented promising data from its Phase 2a trial showing an impressive median overall survival of 17.3 months in 55 first-line pancreatic cancer patients treated with atebimetinib combined with chemotherapy. This outcome notably exceeds the historical median of 8.5 months reported in the standard of care chemotherapy. The trial exhibited only limited severe adverse events and a favorable tolerability profile, with a high percentage of participants maintaining or gaining weight. The ongoing recruitment for the Phase 3 MAPKeeper 301 trial aims to further evaluate atebimetinib's effectiveness in this patient population.
Read more →IMRXImmuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Corporation reported a 17.3-month median overall survival for first-line metastatic pancreatic cancer patients treated with atebimetinib plus chemotherapy in a Phase 2a trial. The trial included 55 patients, with a tolerability profile consistent with prior updates. The company plans to present detailed findings at the ASCO Annual Meeting on June 1, 2026, and is currently recruiting for a pivotal Phase 3 trial.
Read more →IMRXImmuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be pres
Immuneering Corporation has reported positive financial results for Q1 2026, showcasing new survival data from its Phase 2a clinical trial of atebimetinib in first-line metastatic pancreatic cancer set to be presented at the upcoming ASCO Annual Meeting. The company's pivotal Phase 3 MAPKeeper 301 trial is actively recruiting patients, with expectations to dose the first participant by mid-2026. Amid an overall cash position of $198.6 million, which is projected to sustain operations until 2029, Immuneering's developments suggest strong potential in improving treatment outcomes for pancreatic cancer patients.
Read more →IMRXImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Immuneering Corporation announced that new survival data from its Phase 2a clinical trial of atebimetinib combined with mGnP in first-line pancreatic cancer patients will be presented at the 2026 ASCO Annual Meeting. The presentation will include data from an expanded cohort of 55 patients, highlighting the treatment's potential to positively impact survival rates. Immuneering aims to showcase the efficacy of atebimetinib, which is designed to shrink tumors while preserving body mass and ensuring tolerability. This oral presentation marks a key moment for the company as it continues to develop innovative cancer treatments.
Read more →IMRXImmuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Immuneering Corporation presented new genetic data at the 2026 AACR Annual Meeting, highlighting the potential of their drug, atebimetinib, in improving survival for pancreatic cancer patients. The findings indicate that atebimetinib-treated tumors show rare mutations associated with drug resistance, suggesting that it may provide more durable treatment efficacy compared to conventional therapies. The company is expected to initiate a pivotal Phase 3 trial of atebimetinib in combination with chemotherapy in mid-2026, further supporting the drug's promising profile in oncology.
Read more →IMRXImmuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Immuneering Corporation announced that CEO Ben Zeskind will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The company is focused on developing Deep Cyclic Inhibitors, with its lead candidate, atebimetinib, targeting various cancer indications. The pivotal Phase 3 trial for atebimetinib is expected to begin mid-2026.
Read more →IMRXImmuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Immuneering Corporation announced it will present data on atebimetinib at the AACR Annual Meeting in April 2026. The presentation will focus on the drug's ability to shrink tumors durably and mitigate resistance mechanisms in RAS-mutant solid tumors. The findings suggest that atebimetinib may provide a more sustained clinical benefit compared to conventional MAPK inhibitors.
Read more →IMRXImmuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic
Immuneering Corporation reported strong financial results for the fourth quarter and full year 2025, highlighting a 64% overall survival rate in its Phase 2a trial of atebimetinib combined with mGnP in pancreatic cancer patients. The company plans to initiate a pivotal Phase 3 trial, MAPKeeper 301, in mid-2026 after securing FDA and EMA alignment. Despite a substantial cash position and upcoming clinical milestones, Immuneering continues to experience financial losses and rising administrative costs. Nevertheless, their drug candidate, atebimetinib, shows promise in improving overall survival through innovative mechanisms.
Read more →IMRXImmuneering to Present at the Leerink Global Healthcare Conference
Immuneering Corporation will present at the Leerink Global Healthcare Conference on March 9-11, 2026, in Miami. CEO Ben Zeskind will discuss the company's pipeline and business strategy. Immuneering focuses on developing Deep Cyclic Inhibitors to enhance cancer patient survival. The lead candidate, atebimetinib, targets MAPK pathway-driven tumors and is set for a pivotal Phase 3 trial.
Read more →IMRXImmuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Immuneering Corporation (Nasdaq: IMRX) announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, scheduled for February 25-26, 2026. CEO Ben Zeskind and CSO Brett Hall will present the company's pipeline, platform, and business strategy. Immuneering focuses on late-stage clinical oncology and is developing a new class of cancer therapies, with atebimetinib as its lead product candidate slated for evaluation in a Phase 3 trial for pancreatic cancer. The presentation will be available via webcast for interested investors.
Read more →IMRXImmuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Immuneering Corporation announced a promising 64% overall survival rate at 12 months from its Phase 2a trial of atebimetinib combined with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer patients. The median overall survival has not yet been reached, indicating potential for durable clinical benefits. The company is preparing to initiate a pivotal Phase 3 trial, MAPKeeper 301, in mid-2026, following favorable discussions with the FDA and EMA. Continued favorable tolerability has been observed, with no new safety concerns reported.
Read more →IMRXImmuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
Immuneering Corporation will announce 12-month overall survival data from its Phase 2a trial of atebimetinib combined with mGnP for first-line pancreatic cancer on January 7, 2026. The company expresses confidence in the drug's potential to enhance patient outcomes. The data will be shared during a conference call and webcast.
Read more →IMRXImmuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
Immuneering Corporation is set to begin dosing patients in a global Phase 3 trial for atebimetinib in first-line metastatic pancreatic cancer by mid-2026. The company has completed End-of-Phase 2 interactions with the FDA and received scientific advice from the EMA, achieving alignment on trial design. The trial will evaluate atebimetinib in combination with modified gemcitabine and nab-paclitaxel, with a primary endpoint of overall survival.
Read more →IMRXImmuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Immuneering Corporation is set to be added to the Nasdaq Biotechnology Index, effective prior to market open on December 22, 2025. This addition highlights the company's eligibility and performance in the biotechnology sector. Immuneering focuses on developing novel cancer therapies, including its lead product candidate, atebimetinib, which is intended for treating various cancer indications. With a Phase 3 trial planned for mid-2026, the company aims to enhance cancer patients' quality of life.
Read more →IMRXImmuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
Immuneering Corporation reported strong financial results for Q3 2025, highlighting an impressive 86% overall survival rate in pancreatic cancer patients treated with atebimetinib. The company raised $225 million, ensuring funding through 2029, and received a U.S. patent for atebimetinib. Additionally, notable patient responses were documented, supporting the drug's potential in cancer treatment.
Read more →IMRXImmuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
Immuneering Corporation will host a conference call on September 29, 2025, to discuss updated overall survival and safety data from a Phase 2a clinical trial of atebimetinib combined with mGnP in first-line pancreatic cancer patients. The data, which shows promising results, will also be presented at the PanCAN Scientific Summit 2025. The call aims to engage the community in understanding these important findings.
Read more →IMRXImmuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
Immuneering Corporation has announced the pricing of its underwritten public offering of Class A common stock, aiming to raise approximately $175 million. The offering includes an option for underwriters to purchase additional shares. Concurrently, Sanofi will purchase shares in a private placement. Proceeds will support the development of Immuneering's product candidates.
Read more →IMRXImmuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
Immuneering Corporation announced a proposed underwritten public offering of Class A common stock and pre-funded warrants. Concurrently, Sanofi will purchase $25 million in shares as part of a private placement. The proceeds from both transactions are intended to support the development of Immuneering's product candidates. However, the offering is subject to market conditions and may not be completed as planned.
Read more →IMRXImmuneering Appoints Dr. Thomas Schall as Chairman of the Board
Immuneering Corporation has appointed Dr. Thomas Schall as Chairman of the Board. Dr. Schall, a seasoned biotech executive, is expected to leverage his extensive experience in drug development to guide Immuneering through late-stage development of its lead candidate, atebimetinib. His appointment comes as the company prepares for significant upcoming data announcements and pivotal studies.
Read more →IMRXImmuneering Announces Closing of $25 Million Private Placement
Immuneering Corporation announced the successful closing of a $25 million private placement aimed at supporting its oncology drug development. The placement involved the sale of unregistered shares and warrants to institutional investors. The company is focused on developing its lead candidate, atebimetinib, which is currently in a Phase 2a trial for advanced solid tumors.
Read more →IMRXImmuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
Immuneering Corporation has announced a clinical supply agreement with Eli Lilly to evaluate atebimetinib in combination with olomorasib in a Phase 2 trial for advanced non-small cell lung cancer. This collaboration aims to explore the potential of a dual-targeted approach to improve treatment outcomes. Preclinical studies have shown promising results, indicating enhanced tumor regression and prolonged survival.
Read more →IMRXImmuneering Announces $25 Million Private Placement
Immuneering Corporation announced a $25 million private placement aimed at institutional and accredited investors. The proceeds from this placement will support the ongoing Phase 2a trial of their product candidate, atebimetinib, targeting pancreatic cancer. Notably, recent data showed a 94% overall survival rate at 6 months among patients treated with atebimetinib in combination with mGnP. This remarkable response rate has attracted significant interest from investors and pharmaceutical companies alike.
Read more →IMRXImmuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates - Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N 34) treated with atebimetinib + m
Immuneering Corporation reported promising financial results for Q2 2025, highlighting a 94% overall survival rate observed in their Phase 2a trial for atebimetinib in first-line pancreatic cancer patients. The company anticipates sharing updated overall survival and progression-free survival data in Q3 2025. Additionally, Immuneering received a new composition of matter patent for atebimetinib, providing expected exclusivity until 2042. The company has submitted a meeting request to the FDA to plan a pivotal trial for atebimetinib, which is expected to begin in 2026.
Read more →IMRXImmuneering Reports First Quarter 2025 Financial Results and Provides Business Updates - Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-
Immuneering Corporation reported its first quarter 2025 financial results, highlighting positive developments in its Phase 2a trial of IMM-1-104 for pancreatic cancer. The trial showed encouraging patient responses, including complete and partial responses in various treatment settings. The company extended its cash runway into 2026 and announced the appointment of Dr. Igor Matushansky as Chief Medical Officer to lead clinical efforts. However, it also reported a net loss of $15.0 million, indicating ongoing financial challenges.
Read more →IMRXImmuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging resp
Immuneering Corporation has reported positive updates from its Phase 2a trial of IMM-1-104, particularly in pancreatic cancer, where combination therapies showed promising response rates. The company has secured a clinical trial supply agreement with Regeneron Pharmaceuticals for further studies in non-small cell lung cancer. Additionally, Immuneering has appointed Dr. Igor Matushansky as Chief Medical Officer to lead future clinical activities. While the company's cash runway extends into 2026, it has also reported a significant increase in net losses compared to the previous year.
Read more →IMRXImmuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First
Immuneering Corporation reported its third quarter 2024 financial results, highlighting positive initial data for IMM-1-104 in a Phase 2a clinical trial for pancreatic cancer. The company has received FDA Orphan Drug and Fast Track designations for this therapy. While the initial response data showed promising results, Immuneering continues to face financial challenges, reporting a net loss of $14.6 million for the quarter. The company expects additional data from the trial by the end of the year.
Read more →IMRXImmuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2
Immuneering Corporation reported its second quarter 2024 financial results, highlighting significant progress in its clinical trials, particularly the IMM-1-104 Phase 2a trial for pancreatic cancer, which has received FDA Fast Track designation. The company is on track to deliver initial data from multiple arms of this trial in the second half of 2024. Despite promising developments, financial losses increased to $14.1 million compared to the previous year. The company also anticipates that its current cash reserves will fund operations into the second half of 2025.
Read more →IMRXImmuneering Reports First Quarter 2024 Financial Results and Provides Business Updates - Reported Positive Topline Results from Phase 1 Portion of its Phase 1 2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - -
Immuneering Corporation reported its financial results for Q1 2024, announcing positive topline results from the Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104, indicating the treatment's potential for patients with RAS-mutant solid tumors. The company also dosed the first patient in the Phase 2a trial and highlighted promising preclinical data demonstrating synergistic effects when combined with chemotherapy for pancreatic cancer. Despite a net loss increase and rising R&D expenses, the firm expects a data-rich 2024 with initial results anticipated from multiple clinical trial arms.
Read more →IMRXImmuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 1 2a trial of IMM-1-104 expected in March 2024 - - Dosing of first pa
Immuneering Corporation reported its financial results for Q4 and the full year of 2023, highlighting advancements in its clinical trials for drugs IMM-1-104 and IMM-6-415. The company is set to share topline data from the Phase 1 portion of the Phase 1 2a trial of IMM-1-104 in March 2024, with an expanded Phase 2a trial also scheduled to begin dosing its first patient in the same month. Additionally, Immuneering received FDA Fast Track designation for IMM-1-104 in treating pancreatic cancer, underscoring its potential as a significant treatment option.
Read more →IMRXImmuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates -Dose evaluation portion of IMM-1-104 Phase 1 2a trial approximately two-thirds enrolled Immuneering's recommendation for a Phase 2 d
Immuneering Corporation reported its third quarter 2023 financial results, highlighting significant advancements in its clinical trials, particularly the Phase 1 of IMM-1-104. Approximately two-thirds of patients have been enrolled in the trial, with initial data expected in 2024. The company plans to expand to a Phase 2a development plan that includes additional trial arms and anticipates filing an IND for a new candidate, IMM-6-415, in Q4 2023. Financially, Immuneering holds a solid cash position but reported a slight increase in net loss amid rising R&D expenses.
Read more →IMRXImmuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates - Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) ann
Immuneering Corporation announced its financial results for Q2 2023, highlighting the successful completion of the Phase 1a trial for IMM-1-104, targeting RAS-mutant solid tumors. Positive initial data related to pharmacokinetics and safety were presented at the recent AACR meeting. The company's cash runway has been extended into 2025 following a $30 million financing round, and it anticipates further updates and recommendations for Phase 2 dosing early next year. However, the company is still facing significant net losses and the complexities associated with clinical drug development.
Read more →IMRXBuilding a Universal - RAS Franchise Nasdaq: IMRX APRIL 2023 Investor Presentation 2023 Corporate Presentation 2 This presentation contains forward - looking statements within the meaning of the Private Securities Litiga
IMRX has provided a corporate presentation outlining its development prospects for the Universal - RAS franchise, with a focus on the IMM-1-104 candidate. The company's forward-looking statements highlight the ongoing Phase 1/2a clinical trial set to evaluate its potential effectiveness in targeting a range of RAS mutations. Key milestones include expected initial clinical data and updates on the product pipeline, which aims to provide innovative treatments for cancer. However, the company acknowledges numerous risks that could affect its operational and developmental outcomes.
Read more →IMRXImmuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides
Immuneering Corporation reported its financial results for the fourth quarter and full year 2022, highlighting key advancements in its oncology pipeline. The company announced it dosed the first patient in its Phase 1/2a clinical trial for IMM-1-104, aiming to target advanced solid tumors with any RAS mutation. Looking ahead, it provided timelines for upcoming data readouts and extended its cash runway into Q4 2024, although it also reported a significant increase in net loss compared to the prior year and suspended its neuroscience initiatives.
Read more →IMRXImmuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations ( NCT05585320), with
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter Shares
Read more →IMRXImmuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights IND filing for IMM-1-104, which has displayed broad preclinical pan-KRAS/NRAS activity, expected this quarter; Enrollment of first
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights IND filing for IMM-1-104, which has displayed broad preclinical pan-KRAS/NRAS activity, expected this quarter; Enrollment of first patient in planned Phase 1/2a clinical trial expected in Q4
Read more →IMRXImmuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022 IND filing for IMM-6-415, designed
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022 IND filing for IMM-6-415, designed to sensitize resistant tumors to select immunotherapies,
Read more →IMRXImmuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates Lead Product Candidate, IMM-1-104, displays broad activity against a wide range of animal tumor models driven by MAPK
Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates Lead Product Candidate, IMM-1-104, displays broad activity against a wide range of animal tumor models driven by MAPK pathway activating mutations including KRAS-G12D, KRAS-G12S
Read more →IMRXThe field allows up to 17 characters.
The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei_EntityFileNum
Read more →IMRXImmuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company
Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, M
Read more →IMRXImmuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expe
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, Mass.
Read more →Competitive Position
How IMRX ranks across every disease it competes inCompetitive Position is a premium feature
See how IMRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial